Notice2025-09757
Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 30, 2025
Issuing agencies
Trade Representative, Office of United States
Abstract
Pursuant to the Executive Order titled Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients, USTR invites comments from interested parties regarding any act, policy, or practice that may be unreasonable or discriminatory and that has the effect of forcing American patients to pay for a disproportionate amount of global pharmaceutical research and development, including by suppressing the price of pharmaceutical products below fair market value in foreign countries.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 103 (Friday, May 30, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 103 (Friday, May 30, 2025)]
[Notices]
[Pages 23105-23106]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-09757]
-----------------------------------------------------------------------
OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE
Request for Comments Regarding Foreign Nations Freeloading on
American-Financed Innovation
AGENCY: Office of the United States Trade Representative (USTR).
ACTION: Request for comments.
-----------------------------------------------------------------------
SUMMARY: Pursuant to the Executive Order titled Delivering Most-
Favored-Nation Prescription Drug Pricing to American Patients, USTR
invites comments from interested parties regarding any act, policy, or
practice that may be unreasonable or discriminatory and that has the
effect of forcing American patients to pay for a disproportionate
amount of global pharmaceutical research and development, including by
suppressing the price of pharmaceutical products below fair market
value in foreign countries.
DATES: To be assured of consideration, please submit comments by June
27, 2025.
ADDRESSES: Submit written comments through the online USTR portal:
<a href="https://comments.ustr.gov/s/">https://comments.ustr.gov/s/</a>. Follow the instructions for submission in
section III below. The docket number is USTR-2025-0011. For
alternatives to online submissions, please contact Catherine Gibson,
Deputy Assistant U.S. Trade Representative for Monitoring and
Enforcement, at <a href="/cdn-cgi/l/email-protection#0a496b7e626f7863646f2442244d63687965644a7f797e78246f657a246d657c"><span class="__cf_email__" data-cfemail="2a694b5e424f5843444f0462046d43485945446a5f595e58044f455a044d455c">[email protected]</span></a> or 202.395.5725.
FOR FURTHER INFORMATION CONTACT: Catherine Gibson, Deputy Assistant
U.S. Trade Representative for Monitoring and Enforcement, at
<a href="/cdn-cgi/l/email-protection#82c1e3f6eae7f0ebece7accaacc5ebe0f1edecc2f7f1f6f0ace7edf2ace5edf4"><span class="__cf_email__" data-cfemail="a1e2c0d5c9c4d3c8cfc48fe98fe6c8c3d2cecfe1d4d2d5d38fc4ced18fc6ced7">[email protected]</span></a> or 202.395.5725.
SUPPLEMENTARY INFORMATION:
I. Background
On May 12, 2025, the President issued Executive Order 14297 titled
Delivering Most-Favored-Nation Prescription Drug Pricing to American
Patients (E.O.). See 90 FR 20749. The E.O. set out as policy that
Americans should not be forced to subsidize low-cost prescription drugs
and biologics in other developed countries and face overcharges for the
same products in the United States, and therefore that Americans must
have access to the most-favored-nation price for these products. In the
E.O. the President also stated that his Administration will take
immediate steps to end global freeloading and that, should drug
manufacturers fail to offer American consumers the most-favored-nation
lowest price, his Administration will take additional aggressive
action.
To address foreign nations freeloading on American-financed
innovation, the E.O. calls on the U.S. Trade Representative to take all
necessary and appropriate action to ensure foreign countries are not
engaged in any act, policy, or practice that may be unreasonable or
discriminatory and that has the effect of forcing American patients to
pay for a disproportionate amount of global pharmaceutical research and
development, including by suppressing the price of pharmaceutical
products below fair market value in foreign countries.
II. Topics on Which USTR Seeks Information
Pursuant to the E.O., USTR invites comments from interested parties
regarding any act, policy, or practice that may be unreasonable or
discriminatory and that has the effect of forcing American patients to
pay for a disproportionate amount of global pharmaceutical research and
development, including by suppressing the price of pharmaceutical
products below fair market value in foreign countries.
Submissions should set out the foreign country or economy of
concern; the act, policy, or practice of concern; any reason(s) that
act, policy, or practice may be unreasonable or discriminatory, and how
that act, policy, or practice has the effect of forcing American
patients to pay for a disproportionate amount of global pharmaceutical
research and development, including by suppressing the price of
pharmaceutical products below fair market value in foreign countries.
Consistent with its statutory mandate, USTR welcomes ongoing
engagement with and information from any interested party, and this
request for comment should not be understood as the sole opportunity
for an interested party to provide such information. This request for
comments builds upon previous USTR requests for public comments,
including the Request for Comments to Assist in Reviewing and
Identifying Unfair Trade Practices and Initiating All Necessary Actions
to Investigate Harm From Non-Reciprocal Trade Arrangements. See 90 FR
10677. Interested parties may submit a new comment in response to this
request or may rely on comments previously submitted to USTR.
III. Submission Instructions
You must submit written comments in response to this notice using
the appropriate docket on the portal at <a href="https://comments.ustr.gov/s/">https://comments.ustr.gov/s/</a>.
To make a submission, use docket number USTR-2025-0011 entitled
`Request for Comments Regarding Foreign Nations Freeloading on
American-Financed Innovation'. You do not need to establish an account
to submit comments. The first screen allows you to enter identification
and contact information. Third-party organizations such as law firms,
trade associations, or customs brokers should identify the full legal
name of the organization they represent and identify the primary point
of contact for the submission. Fields with a gray Business Confidential
Information (BCI) notation are for BCI information that will not be
made publicly available. Fields with a green (Public) notation will be
viewable by the public. After entering the identification and contact
information, you can
[[Page 23106]]
complete the remainder of the comment, or any portion of it, by
clicking `Next.' You may upload documents at the end of the form and
indicate whether USTR should treat the documents as business
confidential or public information. Any page containing BCI must be
clearly marked `BUSINESS CONFIDENTIAL' on the top of that page and the
submission should clearly indicate, via brackets, highlighting, or
other means, the specific information that is BCI. If you request
business confidential treatment, you must certify in writing that the
information would not customarily be released to the public. Parties
uploading attachments containing BCI also must submit a public version
of their comments. If these procedures are not sufficient to protect
BCI or otherwise protect business interests, please contact Catherine
Gibson at <a href="/cdn-cgi/l/email-protection#0a496b7e626f7863646f2442244d63687965644a7f797e78246f657a246d657c"><span class="__cf_email__" data-cfemail="387b594c505d4a51565d1670167f515a4b5756784d4b4c4a165d5748165f574e">[email protected]</span></a> or 202.395.5725 to discuss
whether alternative arrangements are possible. USTR will post
attachments uploaded to the docket for public inspection, except for
properly designated BCI. You can view submissions on USTR's electronic
portal at <a href="https://comments.ustr.gov/s/">https://comments.ustr.gov/s/</a>.
Jennifer Thornton,
General Counsel, Office of the United States Trade Representative.
[FR Doc. 2025-09757 Filed 5-29-25; 8:45 am]
BILLING CODE 3390-F4-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 30, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.